Newer patents in antimycobacterial therapy

Papers of special note have been highlighted as: • of interest

References

• 1 Keshavjee S, Farmer PE. 200th anniversary article: tuberculosis, drug resistance and the history of modern medicine. N. Engl. J. Med. 367, 931–936 (2012).
  Medline CASGoogle Scholar
• 2 Zumla A, Raviglione M, Hafner R, Fordham von Reyn C. Current concepts: tuberculosis. N. Engl. J. Med. 368, 745–755 (2013).
  Medline CASGoogle Scholar
• 3 World Health Organization. WHO Report 2014: Global Tuberculosis Control. WHO/HTM/TB/2014.19. www.who.int/tb/publications/global_report/en/.
  Google Scholar
• 4 van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 53(3), 849–862 (2009).• Detailed discussion on some new antituberculosis agents
  Medline CASGoogle Scholar
• 5 Dasgupta SB, Pieters J. Striking the right balance determines TB or not TB. Front. Immunol. 5, 455–463 (2014).• Vivid description of the pathogenesis, virulence factors and host immunity.
  MedlineGoogle Scholar
• 6 Rhee KY, de Carvalho LPS, Bryk R et al. Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier. Trends Microbiol. 19(7), 307–314 (2011).
  Medline CASGoogle Scholar
• 7 Griffin JE, Pandey AK, Gilmore SA et al. Cholesterol metabolism in Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem. Biol. 19(2), 218–227 (2012).
  Medline CASGoogle Scholar
• 8 Butov DO, Yanovsky FG, Kuzhko MM et al. Dynamics of oxidant-antioxidant system in patients with multidrug-resistant tuberculosis receiving anti-mycobacterial therapy. J. Pulm. Respir. Med. 3(5), 161 (2013).
  Google Scholar
• 9 Bharati BK, Chatterji D. Quorum sensing and pathogenesis: role of small signalling molecules in bacterial persistence. Curr. Sci. 105(5), 643–656 (2013).
  CASGoogle Scholar
• 10 Kumar R. Glyoxylate shunt: combating mycobacteria at forefront. Int. J. Integr. Biol. 7(2), 69–72 (2009).
  CASGoogle Scholar
• 11 Jozefowski S, Sobota A, Kwiatkowska K. How Mycobacterium tuberculosis subverts host immune responses. BioEssays 30, 943–954 (2008).
  Medline CASGoogle Scholar
• 12 Elkington PT, Ugrate-Gil CA, Friedland JS. Matrix metalloproteinases in tuberculosis. Eur. Respir. J. 38(2), 456–464 (2011).
  Medline CASGoogle Scholar
• 13 Lienhardt C, Raviglione M, Spigelman M et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis. 205(S2), S241–249 (2012).• Elaborate description about novel antimycobacterial drugs and their future.
  MedlineGoogle Scholar
• 14 Tam C-M, Yew WW, Yuen K-Y. Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects. Expert Rev. Clin. Pharmacol. 2(4), 405–421 (2009).
  Medline CASGoogle Scholar
• 15 Sarkar S, Mavanur RS. An overview of tuberculosis chemotherapy-a literature review. J. Pharm. Pharm. Sci. 14(2), 148–161 (2011).
  Medline CASGoogle Scholar
• 16 Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit. Rev. Ther. Drug Carrier Syst. 31(1), 49–88 (2014).
  Medline CASGoogle Scholar
• 17 Tomioka H. Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Curr. Pharm. Des. 20(27), 4305–4306 (2014).
  Medline CASGoogle Scholar
• 18 Ganihigama DU et al. Antimycobacterial activity of natural products and synthetic agents: pyrroloquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. Eur. J. Med. Chem. 89, 1–12 (2015).
  Medline CASGoogle Scholar
• 19 Lai HM, Mazlan NA, Yusoff MS, Harun SN, Wee LJ, Thambrin MF. Management of side effects and drug interactions of anti-mycobacterial in tuberculosis. WebmedCentral INFECTIOUS DISEASES 2(12), WMC002749 (2011).
  Google Scholar
• 20 Vora C, Patadia R, Mittal K, Mashru R. Recent patents and advances on anti-tuberculosis drug delivery and formulations. Recent Pat. Drug Deliv. Formul. 20137(2), 138–149 (2013).• Detailed account about newer drug delivery technologies and their application to tuberculosis.
  Google Scholar
• 21 Limonov VL. WO2154077 (2012).
  Google Scholar
• 22 du Toit LC, Danckwerts MP, Pillay V, Cooppan S, Choonara YE. US0179170 (2010).
  Google Scholar
• 23 Noa Sic Aps: US8623864 (2014).
  Google Scholar
• 24 Simons SO, Kristiansen JE, Hajos G et al. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. Int. J. Antimicrob. Agents 41(5), 488–489 (2013).
  Medline CASGoogle Scholar
• 25 Adams KN, Szumowski JD, Ramakrishnan L. Verapamil and its metabolite norverapamil inhibit macrophage-induced, bacterial efflux-pump-mediated tolerance to multiple anti-tubercular drugs. J. Infect. Dis. 210(3), 456–466 (2014).
  Medline CASGoogle Scholar
• 26 Placido R, Auricchio G, Falzoni S et al. P2X(7) purinergic receptors and extracellular ATP mediated apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability. Cell. Immunol. 244(1), 10–18 (2006).
  Medline CASGoogle Scholar
• 27 Parabolic Biologicals SPRL: WO1160684 (2011).
  Google Scholar
• 28 US Department of Health and Human Services: WO3019926 (2013).
  Google Scholar
• 29 The International Centre for Diarrhoeal Disease Research: WO2140504 (2012).
  Google Scholar
• 30 Summit Corp Plc.: WO8009894 (2008).
  Google Scholar
• 31 Hemphill TA. The NIH promotes drug repurposing and rescue. Research-Technology Management 55(5), September/October (2012).
  Google Scholar
• 32 Diacon AH et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380(9846), 986–993 (2012).
  Medline CASGoogle Scholar
• 33 Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug resistant tuberculosis. N. Engl. J. Med. 367, 1508–1518 (2012).
  Medline CASGoogle Scholar
• 34 van Ingen J. The broad-spectrum antimycobacterial activities of phenothiazines, In vitro: somewhere in all of this there may be patentable potentials. Recent Pat Antiinfect Drug Discov 6(2), 104–109 (2011).
  Medline CASGoogle Scholar
• 35 Bkg Pharma Aps. US0066451 (2014).
  Google Scholar
• 36 The Trustees of Columbia University in the city of New York: US0199289 (2014).
  Google Scholar
• 37 Horita Y, Takii T, Yagi T et al. Anti-tubercular activity of Disulfiram, an anti-alcoholism drug, against multi-drug and extensively drug-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 56(8), 4140–4145 (2012).
  Medline CASGoogle Scholar
• 38 Cornell Research Foundation Inc. US0118274 (2011).
  Google Scholar
• 39 Kazakhstan Enterprises Research Centre: WO2091534 (2012).
  Google Scholar
• 40 Nabriva Theraprutics Ag. US8088823 (2012).
  Google Scholar
• 41 Activbiotics Pharma Llc. WO2103119 (2012).
  Google Scholar
• 42 Activbiotics Pharma Llc. WO2203116 (2012).
  Google Scholar
• 43 Rychtarčíková Z, Krátký M, Gazvoda M et al. N-substituted 2-isonicotinoylhydrazinecarboxamides-new antimycobacterial active molecules. Molecules 19, 3851–3868 (2014).
  MedlineGoogle Scholar
• 44 Campos MM. Preclinical evaluation of novel anti-tuberculosis molecules. BMC Proc. 8(Suppl 4), O17 (2014).
  Google Scholar
• 45 Sequella Inc. US US7884097 (2011).
  Google Scholar
• 46 Shirude PS, Madhavapeddi P, Tucker JA et al. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium Tuberculosis. ACS Chem. Biol. 8(3), 519–523 (2013).
  Medline CASGoogle Scholar
• 47 Lu Y, Zheng M, Wang B et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation Antimicrob. Agents Chemother. 55(11), 5185–5193 (2011).
  Medline CASGoogle Scholar
• 48 Institute Materia Medica/Beijing Tuberculosis and Thoracic Tumor Research Institute. US0243327 (2014).
  Google Scholar
• 49 Kamal A, Azeeza S, Malik MS, Shaik AA, Rao MV. Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds. J. Pharm. Pharm. Sci. 11(2), 56s–80s (2008).• Discussion about current and newer anti-TB drugs and detailed narration on thiolactomycin and its derivatives.
  Medline CASGoogle Scholar
• 50 Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multi drug resistant pulmonary tuberculosis N Engl J Med 366, 2151–2160 (2012).
  Medline CASGoogle Scholar
• 51 Rawat B, Rawat DS. Antituberculosis drug research: a critical overview. Med. Res. Rev. 33, 693–764 (2013).
  MedlineGoogle Scholar
• 52 Janssen Pharmaceutica N.V. US7498343 (2009).
  Google Scholar
• 53 Lechartier B, Rybniker J, Zumla A, Cole ST. Tuberculosis drug discovery in the post-post genomic era. EMBO Mol. Med. 6(2): 158–168 (2014).• Special notes on new antimycobacterial molecules and drug targets.
  Medline CASGoogle Scholar
• 54 Lupin Limited: US7691837 (2010).
  Google Scholar
• 55 Astrazeneca Ab: US2035219 (2012).
  Google Scholar
• 56 Molina-Torres CA, Barba-Marines A, Valles-Guerra O et al. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Annals of Clinical Mircobiology and Antimicrobials 13(1), 13–17 (2014).
  MedlineGoogle Scholar
• 57 Trius Therapeutics Inc. US0102523 (2013).
  Google Scholar
• 58 Ranbaxy Lab Ltd. WO6043121 (2006).
  Google Scholar
• 59 Lupin Limited. US7691889 (2010).
  Google Scholar
• 60 Joint Stock Company ‘Pharmasyntez’. US0052265 (2013).
  Google Scholar
• 61 ETH Zurich. WO4040709 (2014).
  Google Scholar
• 62 Meiji Seika Kaisha Ltd, Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai. US0005371 (2014).
  Google Scholar
• 63 Sequella Inc. US0281054 (2009).
  Google Scholar
• 64 Siricilla S, Mitachi K, Wan B, Franzblau SG, Kurosu M. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors. J. Antibiot. (Tokyo) doi:10.1038/ja.2014.133 (2014) (Epub ahead of print).
  MedlineGoogle Scholar
• 65 Daiichi Sankyo Company Limited US8476429 (2013).
  Google Scholar
• 66 Achillon Pharmaceuticals Inc. US0114601 (2012).
  Google Scholar
• 67 Briguglio I, Piras S, Corona P, Antonietta Pirisi M, Jabes D, Carta A. SAR and anti-mycobacterial activity of quinolones and triazoloquinolones: an update. Anti-Infect. Agents 11(1), 75–89 (2013).
  CASGoogle Scholar
• 68 Garg HK, Shrivastava A. Evaluation and impact of anti-tuberculosis drug: a review. Int. J. Sci. Res. 2(7), doi:10.15373/22778179/July2013/8 (2013).
  Google Scholar
• 69 University of Tennessee Research Foundation. US0249155 (2014).
  Google Scholar
• 70 B & C Biopharm.: WO2144790 (2012).
  Google Scholar
• 71 Ocean university of China. CN102603525 (2012).
  Google Scholar
• 72 Council of Scientific and Industrial Research. US8865910 (2012).
  Google Scholar
• 73 University of Virginia Patent Foundation. US0317070 (2013).
  Google Scholar
• 74 Indian Council of Scientific and Industrial Research. WO2164572 (2012).
  Google Scholar
• 75 Jenrin Discovery. WO2068560 (2012).
  Google Scholar
• 76 Sequella Inc.: US8198303 (2012).
  Google Scholar
• 77 Pethe K, Bifani P, Jang J et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19(9), 1157–1160 (2013).
  Medline CASGoogle Scholar
• 78 The Research Foundation of State University of New York. US8232410 (2012).
  Google Scholar
• 79 Meyyanathan SN. IP254676 (2012).
  Google Scholar
• 80 Universidade Estadual Paulista Julio De Mesquita Filho-UNESP. WO1137503 (2011).
  Google Scholar
• 81 Unither Virology, Llc. WO4143999 (2014).
  Google Scholar
• 82 Universiteit Utrecht Holding B.V., Stichting Voor De Technische Wetenschappen. WO4017915 (2014).
  Google Scholar
• 83 GlaxoSmithKline. US0288133 (2014).
  Google Scholar
• 84 Glaxo Group Limited. US0203802 (2013).
  Google Scholar
• 85 Glaxo Group Limited. US0095064 (2012).
  Google Scholar
• 86 Agency for Science, Technology and Research, Singapore Health Services Pte Ltd.: WO3036207 (2013).
  Google Scholar
• 87 The Broad Institute Inc. and Massachusetts General Hospital. WO3049567 (2013).
  Google Scholar
• 88 Vertex Pharmaceuticals Incorporated. WO1019405 (2011).
  Google Scholar
• 89 Klein LL, Petukhova V, Wan B et al. A novel indigoid anti-tuberculosis agent. Bioorg. Med. Chem. Lett. 24(1), 268–270 (2014).
  Medline CASGoogle Scholar
• 90 Sanofi US0245008 (2013).
  Google Scholar
• 91 Sichuan University. WO2162912 (2012).
  Google Scholar
• 92 Lilienkampf A, Pieroni M, Franzblau SG, Bishai WR, Kozikowski AP. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis. Curr. Top. Med. Chem. 12, 729–734 (2012).
  Medline CASGoogle Scholar
• 93 Onajole OK, Govender K, Govender P et al. Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents. Eur. J. Med. Chem. 44(11), 4297–4305 (2009).
  Medline CASGoogle Scholar
• 94 The Regents of the University of Colorado. EP2520654 (2012).
  Google Scholar
• 95 Cornell University. US0190234 (2011).
  Google Scholar
• 96 President and Fellows of Harvard College. US0243255 (2014).
  Google Scholar
• 97 Hodges RS, Ziqing J. US0099614 (2010).
  Google Scholar
• 98 Khara JS, Wang Y, Ke XY et al. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin. Biomaterials 35(6), 2032–2038 (2014).
  Medline CASGoogle Scholar
• 99 Forchungzentrum Borstel, Christian-Albrechts-Universitat Zu Kiel. WO1047814 (2011).
  Google Scholar
• 100 Cumbre Pharmaceuticals Inc. US0143373 (2009).
  Google Scholar
• 101 University of Georgia Research Foundation Inc. WO3148174 (2013).
  Google Scholar
• 102 Sachdeva P, Misra R, Tyagi AK, Singh Y. The sigma factors of Mycobacterium tuberculosis: regulation of the regulators. FEBS J. 277(3), 605–626 (2010).
  Medline CASGoogle Scholar
• 103 Ryndak M, Wang S, Smith I. PhoP, a key player in Mycobacterium tuberculosis virulence. Trends Microbiol. 16, 528–534 (2008).
  Medline CASGoogle Scholar
• 104 Leblanc C, Prudhomme T, Tabouret G et al. 4′-phosphopantetheinyl transferase PptT, a new drug target required for Mycobacterium tuberculosis growth and persistence in vivo. PLoS Pathog. 8(12), e1003097 (2012).
  Medline CASGoogle Scholar
• 105 GlaxoSmithKline. WO2143522 (2012).
  Google Scholar
• 106 Novartis Ag. WO4037900 (2014).
  Google Scholar
• 107 Grzegorzewicz AE, Pham H, Gundi VA et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8, 334–341 (2012).
  Medline CASGoogle Scholar
• 108 Arvind A, Kumar V, Saravanan P, Mohan CG. Homology modelling, molecular dynamics and inhibitor binding study on MurD ligase of Mycobacterium tuberculosis. Interdiscip. Sci. 4(3), 223–238 (2012).
  Medline CASGoogle Scholar
• 109 Leibniz Inst Naturstoff Forsch. US0286130 (2010).
  Google Scholar
• 110 Ecole Polytechnique Federale de Lausanne (Epfl). WO0245007 (2013).
  Google Scholar
• 111 Chatterji M, Shandil R, Manjunatha MR et al. 1,4-azaindole, a potential drug candidate for treatment of tuberculosis. Antimicrob. Agents Chemother. 58(9), 5325–5331 (2014).
  Medline CASGoogle Scholar
• 112 Panda M, Ramachandran S, Ramachandran V et al. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J. Med. Chem. 57(11), 4761–4771 (2014).
  Medline CASGoogle Scholar
• 113 Mann FM, Xu M, Deavenport EK, Peters RJ. Functional characterization and evolution of the isotuberculosinol operon in mycobacterium tuberculosis and related mycobacteria. Front. Microbiol. 3, 368 (2012).
  MedlineGoogle Scholar
• 114 Huang X, Huang H, Li H et al. Asperterpenoid A, a new sesterterpenoid as an inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B from the culture of Aspergillus sp. 16–5c. Org. Lett. 15(4), 721–723 (2013).
  Medline CASGoogle Scholar
• 115 Mckenny ES, Sargent M, Khan H et al. Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy. PLoS ONE 7(10), E38167 (2012).
  MedlineGoogle Scholar
• 116 George Washington University et al: WO3006444 (2013).
  Google Scholar
• 117 Smith JM, Warringtom NV, Vierling RJ et al. Targeting DXP synthase in human pathogens: enzyme inhibition and antimicrobial activity of butylacetylphosphonate. J. Antibiot. 67, 77–83 (2014).
  Medline CASGoogle Scholar
• 118 Indiana University Research and Technology Corporation. WO2149049 (2012).
  Google Scholar
• 119 FASgen Inc., The John Hopkins University. US0135568 (2006).
  Google Scholar
• 120 Cornell Research Foundation Inc., Sloan-Kettering Institute for Cancer Research. US0024611 (2014).
  Google Scholar
• 121 University of Notre Dame Du Lac. US6310058 (2001).
  Google Scholar
• 122 The Texas A and M university system. US8664255 (2014).
  Google Scholar
• 123 Lucile WE, Reynolds RC, Suling WJ. US0113429 (2010).
  Google Scholar
• 124 University of Pittsburgh of the Commonwealth system of Higher Education. US0331460 (2013).
  Google Scholar
• 125 Gilead Sciences Inc. US7427624 (2008).
  Google Scholar
• 126 Uti Limuted Partnership. US0070860 (2008).
  Google Scholar
• 127 Hawn TR, Matheson AI, Maley SN, Vandal O. Host-directed therapeutics for Tuberculosis: can we harness the host? Microbiol. Mol. Biol. Rev. 77(4), 4608–4627 (2013).
  Google Scholar
• 128 van der Vaart M, Korbee CJ, Lamers GE et al. The DNA damage-regulated autophagy modulator DRAM1 links mycobacterial recognition via TLP-MYD88 to autophagic defense. Cell host microbe 15(6), 753–767 (2014).
  Medline CASGoogle Scholar
• 129 University of Pittsburgh of the Commonwealth system of Higher Education: WO3134416 (2013).
  Google Scholar
• 130 Stanley SA, Barczak AK, Silvis MR et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10(2): e1003946 (2014).
  MedlineGoogle Scholar
• 131 Avi Biopharma. WO2064991 (2012).
  Google Scholar
• 132 Rath M. WO2177520 (2012).
  Google Scholar
• 133 Orme IM. Vaccine development for tuberculosis: current progress. Drugs 73, 1015–1024 (2013).
  Medline CASGoogle Scholar
• 134 The Regents of the University of California. US8163294 (2012).
  Google Scholar
• 135 Universidade Federal de Minas Gerais. WO2088577 (2012).
  Google Scholar
• 136 Isis Innovation Limited. WO2052748 (2012).
  Google Scholar
• 137 Uab Research Foundation. WO3033363 (2013).
  Google Scholar
• 138 King's College of London, St. George's University of London, University of Dundee. WO2076868 (2012).
  Google Scholar
• 139 University of Central Florida Research Foundation Inc. EP2771469 (2013).
  Google Scholar
• 140 Panseeta P, Lomchoey K, Prabpai S et al. Antiplasmodial and antimycobacterial cyclopeptide alkaloids from the root of Ziziphus mauritiana. Phytochemistry 72(9), 909–915 (2011).
  Medline CASGoogle Scholar
• 141 Billings Pharmaceuticals Inc. US7321002 (2008).
  Google Scholar
• 142 Samad A, Sultana Y, Akhter MS, Aqil M. Treatment of tuberculosis: use of active pharmaceuticals. Recent Pat. Antiinfect. Drug Discov. 3(1), 34–44 (2008).
  Medline CASGoogle Scholar
• 143 Council of Scientific and Industrial Research. US0171498 (2014).
  Google Scholar
• 144 Martins D, Carrion LL, Ramos DF et al. Anti-tuberculosis activity of oleanolic acid and ursolic acid isolated from the dichlormethane extract of leaves from Duroia macrophylla. BMC Proc. 8(Suppl. 4), P3 (2014).
  Google Scholar
• 145 Mann A, Ibrahim K, Oyewale AO, Amupitan JO, Fatope MO, Okogun JL. Antimycobacterial Friedelane-terpenoid from the root bark of Terminalia Avicennioides. Am. J. Chem. 1(2), 52–55 (2011).
  Google Scholar
• 146 Council of Scientific and Industrial Research. US0040007 (2013).
  Google Scholar
• 147 Yale University. US0101688 (2013).
  Google Scholar